NURIX THERAPEUTICS, INC. (NRIX) Overview
- 1 Mar 2026: Period ending 31 May 2026; Estimate (m); Actual -0.81; Beat / miss (m).
- 1 Dec 2025: Period ending 28 Feb 2026; Estimate (m); Actual -0.79; Beat / miss (m).
- 1 Jun 2025: Period ending 31 Aug 2025; Estimate (m); Actual -1.03; Beat / miss (m).
- 1 Mar 2025: Period ending 31 May 2025; Estimate (m); Actual -0.52; Beat / miss (m).
Stock Price Chart
View more →Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
- Last close
- $23.67
- Previous close
- $23.67
- Change
- $0.00
- Change (%)
- 0.02%
- Close date
- 2026-09-29
- Previous close date
- 2026-09-28
- Open
- (m)
- Day high
- (m)
- Day low
- (m)
- Last session volume
- (m)
- Last session value
- (m)
- Currency
- USD
- Price basis
- split-adjusted
- Volume basis
- (m)
Performance
View more →Cumulative total returns · 2026-09-29
YTD
- NRIX
- +24.80%
- S&P 500
- (m)
1 year
- NRIX
- +155.12%
- S&P 500
- (m)
3 years
- NRIX
- +201.21%
- S&P 500
- (m)
5 years
- NRIX
- -19.69%
- S&P 500
- (m)
Earnings trends
View more →Earnings per share
USD / share · As filed
31 May 2026 ○ Estimate (m) ● Actual -0.81
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Mar 2026 | 31 May 2026 | (m) | -0.81 | (m) | (m) |
| 1 Dec 2025 | 28 Feb 2026 | (m) | -0.79 | (m) | (m) |
| 1 Jun 2025 | 31 Aug 2025 | (m) | -1.03 | (m) | (m) |
| 1 Mar 2025 | 31 May 2025 | (m) | -0.52 | (m) | (m) |
| 1 Dec 2024 | 28 Feb 2025 | (m) | -0.67 | (m) | (m) |
30 Nov 2025 ○ Estimate (m) ● Actual -3.05
Comparison details
| Period start | Period ending | Estimate | Actual | Beat / miss | Report date |
|---|---|---|---|---|---|
| 1 Dec 2024 | 30 Nov 2025 | (m) | -3.05 | (m) | (m) |
| 1 Dec 2023 | 30 Nov 2024 | (m) | -2.88 | (m) | (m) |
| 1 Dec 2022 | 30 Nov 2023 | (m) | -2.65 | (m) | (m) |
| 1 Dec 2021 | 30 Nov 2022 | (m) | -3.71 | (m) | (m) |
| 1 Dec 2020 | 30 Nov 2021 | (m) | -2.73 | (m) | (m) |
(m)
Revenue vs. Earnings
USD
31 May 2026 ■ Revenue 9.04M ■ Earnings -89.53M — Profit margin -990.10%
30 Nov 2025 ■ Revenue 83.98M ■ Earnings -264.46M — Profit margin -314.90%
Analyst insights
View more →| Ratings | Buy | Hold | Sell | Other ratings | Last Close | Average Target | Upside | High Target | Low Target |
|---|---|---|---|---|---|---|---|---|---|
| (m) | (m) | (m) | (m) | (m) | $23.67 | (m) | (m) | (m) | (m) |
Recent news
View more →(m)
YouTube videos mentioning NRIX
View more →(m)
Statistics
View more →Retained observations as of 2026-11-11; financial period ending 31 May 2026.
- Forward P/E
- (m)
- PEG ratio · 5-year expected
- (m)
- Shares held by insiders
- (m)
- Insider transactions · change (%)
- (m)
- Shares held by institutions
- (m)
- Institutional transactions · change (%)
- (m)
- Diluted EPS · 12 month
- (m)
- EPS estimate · next quarter
- (m)
- EPS estimate · next year
- (m)
- EPS growth · current annual estimate
- (m)
- EPS growth · next annual estimate
- (m)
- EPS growth · next 5 years expected
- (m)
- EPS growth · past 3 years annualized
- (m)
- EPS growth · past 5 years annualized
- (m)
- EPS change · 12 months vs prior year
- (m)
- EPS change · latest quarter vs previous quarter
- (m)
- Latest earnings report date
- (m)
- EPS surprise · latest reported quarter
- (m)
- Net income · 12 month
- $-341.35M
- Operating margin · 12 months
- -982.37%
- Profit margin
- -928.44%
- Return on assets · 12 month
- -60.57%
- Named executive and board stock awards · latest fiscal year
- (m)
- Index membership
- (m)
- Employees
- 317.00
- IPO date
- (m)
- Options available
- (m)
- Shortable
- (m)
- Analyst recommendation
- (m)
- Analyst target price
- (m)
- Price volatility · week
- (m)
- Price volatility · month
- (m)
- Average true range · 14 sessions
- (m)
- Relative strength index · 14 sessions
- (m)
- Relative volume
- (m)
- Average daily volume
- 1.55M
- Latest session volume
- (m)
- Last session value
- (m)
- 30 days ago session value
- (m)
- 1 year ago session value
- (m)
- Number of trades
- (m)
- Total return · week
- -7.77%*
- Total return · month
- -9.67%*
- Total return · quarter
- -0.73%*
- Total return · half year
- 60.40%*
- Total return · year to date
- 24.80%*
- Total return · 1 year
- 155.12%*
- Total return · 3 years
- 201.21%*
- Total return · 5 years
- -19.69%*
- Market cap
- (m)
- Book value per share · latest quarter
- (m)
- Price / cash · latest quarter
- (m)
- Enterprise value
- (m)
- Enterprise value / revenue
- (m)
- Enterprise value / EBITDA
- (m)
- Dividend · 12 months per share
- (m)
- Dividend ex-date
- (m)
- Next dividend ex-date
- (m)
- Next dividend amount per share
- (m)
- Dividend growth · 3 years annualized
- (m)
- Dividend growth · 5 years annualized
- (m)
- R&D / revenue · 12 months
- 927.31%
- Revenue · 12 month
- $36.77M
- Revenue growth · past 3 years annualized
- (m)
- Revenue growth · past 5 years annualized
- (m)
- Revenue change · 12 months vs prior year
- (m)
- Revenue change · latest quarter vs previous quarter
- (m)
- Revenue surprise · latest reported quarter
- (m)
- Operating cash flow · 12 months
- $-293.70M
- Free cash flow · 12 months (USD)
- $-304.53M
- Levered free cash flow · 12 month
- (m)
- Debt / equity · latest quarter
- (m)
- Long-term debt / equity · latest quarter
- (m)
- Return on equity · 12 month
- (m)
- Return on invested capital · 12 months
- (m)
- Previous close
- (m)
- Latest closing price
- (m)
- Latest session change (%)
- (m)
- 52-week high
- (m)
- 52-week low
- (m)
- Price vs 20-session moving average
- (m)
- Price vs 50-session moving average
- (m)
- Price vs 200-session moving average
- (m)
- Float shares
- (m)
- Short float (%)
- (m)
- Short ratio (days to cover)
- (m)
- Short interest (shares)
- (m)
Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.
Holders breakdown
View more →| Breakdown | Ownership |
|---|---|
| (m) | Shares held by all insiders |
| (m) | Shares held by institutions |
| (m) | Float held by institutions |
| (m) | Institutions holding shares |
Other holders
(m)
Insider holders
(m)
Top institutional holders
(m)
Top mutual fund holders
(m)
NURIX THERAPEUTICS, INC. Overview
View more →(m)
(m)
- SEC CIK
- 1549595
- Industry (SIC)
- 2834 Pharmaceutical Preparations
- Country of operation
- United States
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, California, 94005, United States
- Fiscal year end
- 1130
- Phone
- (415) 660-5320
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |